Nelfinavir

Drugs

Volumn 54, Issue 1, 1997, Pages 81-87

  Perry, C M ^a   Benfield, P ^a   Breckenridge, A ^a   Gathe J C , Jr ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONCENTRATION LOSS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG ELIMINATION; FATIGUE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; NONHUMAN; REVIEW;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030841086     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754010-00007     Document Type: Review

References (30)

1. 1. BV Shetty MB Kosa DA Khalil 1996 Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease Antimicrob Agents Chemother 40 110 4 8787890 1:CAS:528:DyaK28XhvFOisw%3D%3D Shetty BV, Kosa MB, Khalil DA, et al. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996 Jan; 40: 110–4
2. 2. Kaplan AH, Zack JA, Knigge M, et al. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 1993 (67): 4050–5
3. 3. C Peng BK Ho TW Chang 1989 Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity J Virol 63 2550 6 2657099 1:CAS:528:DyaL1MXkt1Sksr8%3D Peng C, Ho BK, Chang TW, et al. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol 1989; 63: 2550–6
4. 4. Shetty B, Kaldor S, Kalish V, et al. AG1343, an orally bioavailable non-peptidic HIV-1 protease inhibitor [abstract]. 10th International Conference on AIDS; 1994 Aug 7–12; Yokohama, 7
5. 5. Patick AK, Mo H, Markowitz M, et al. In vitro antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV-1 protease [abstract]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29–Feb 2; Washington, DC, 88
6. 6. AK Patick H Mo M Markowitz 1996 Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease Antimicrob Agents Chemother 40 292 7 8834868 1:CAS:528:DyaK28Xos1Wnug%3D%3D Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996; 40: 292–7
7. 7. Webber S, Khalil D, Kosa M, et al. Preclinical toxicokinetic studies with AG1343, an orally bioavailable HIV-1 protease inhibitor [abstract]. 2nd National Conference on Retroviruses and Related Infections; 1995 Jan 29–Feb 2, 71
8. 8. Agouron Pharmaceuticals Inc. Nelfinavir mesylate prescribing information. La Jolla (CA), 1997
9. 9. G Moyle B Gazzard 1996 Current knowledge and future prospects for the use of HIV protease inhibitors Drugs 51 701 12 8861542 10.2165/00003495-199651050-00001 1:CAS:528:DyaK28XjsVehsbg%3D Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51: 701–12
10. 10. AK Patick M Duran Y Cao 1996 HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir are not cross-resistant to other protease inhibitors [abstract] AIDS 10 2 OP9.2 Patick AK, Duran M, Cao Y, et al. HIV-1 variants isolated from patients treated with the protease inhibitor, nelfinavir are not cross-resistant to other protease inhibitors [abstract]. AIDS 1996; 10 Suppl. 2: OP9.2
11. 11. Patick AK, Duran M, Cao Y, et al. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T or AZT and 3TC [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC, no. 10
12. 12. Anon. Patterns of resistance to protease inhibitors. Inpharma 1996 Aug 3; 1048: 11
13. 13. Markowitz M, Conant M, Hurley A, et al. Phase I/II dose range-finding study of the HIV protease inhibitor AG1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother. 1995 Sep 17–20 Program Addendum: 8
14. 14. Quart BD, Chapman SK, Peterkin J, et al. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343 — a novel HIV protease inhibitor [abstract]. 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29–Feb 2: 167
15. 15. M Youle G Moyle S Chapman 1995 Phase I/II study of AG1343, a novel HIV protease inhibitor [abstract] Can J Infect Dis 6 C 369C Youle M, Moyle G, Chapman S, et al. Phase I/II study of AG1343, a novel HIV protease inhibitor [abstract]. Can J Infect Dis 1995 Jul; 6 Suppl. C: 369C
16. 16. Moyle G, Youle M, Chapman S, et al. A phase II dose escalation study of the Agouron protease inhibitor AG 1343 [abstract]. 35th Int Conf Antimicrob Agents Chemother. 1995 Sep 17–20 Program Addendum: 8
17. 17. Webber S, Shetty B, Wu E, et al. In vitro and in vivo metabolism and cytochrome P450 induction studies with the HIV-1 protease inhibitor, Viracept (Rm) (AG1343) [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1: Washington, DC, 79
18. 18. Kerr B, Lee C, Yuen G, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate (NFV), a new HIV-1 protease inhibitor [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC, no. 373
19. 19. Kempf D, Marsh K, Denissen J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstract]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28–Feb 1, Washington, DC, 79
20. 20. Pedneault L, Elion R, Adler M, et al. Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DC, no. 241
21. 21. Krogstad P, Kerr B, Anderson R, et al. Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV+ children [abstract]. 4th Conference on Retroviruses and Opportunistic Infections. 1997 Jan 22–26; Washington, DC, no. 721
22. 22. Conant M, Markowitz M, Hurley A, et al. A randomized phase II dose range-finding study of the HIV protease inhibitor Viracept™ as monotherapy in HIV positive patients [abstract]. 11th International Conference on AIDS; 1996 Jul 7–12; Vancouver, 286–7
23. 23. Gathe JJ, Burkhardt B, Hawley P, et al. A randomized phase II study of Viracept™, a novel HIV protease inhibitor, used in combination with stavudine vs. stavudine alone [abstract]. 11th International Conference on AIDS; 1996 Jul 7–12; Vancouver, 25
24. 24. Clinical trials update. Scrip 1996 Jun 18 (2138): 20
25. 25. Henry K, Lamarca A, Myers R, et al. The safety of VIRACEPT® (nelfinavir mesylate) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC [Poster]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC
26. 26. Markowitz M, Winslow D, Cao Y, et al. Triple therapy with nelfinavir (Viracept®) in combination with AZT and 3TC in 12 antiviral-naive subjects chronically infected with HIV-1 [abstract]. Tenth International Conference on Antiviral Research; 1997 Apr 6–11; Atlanta
27. 27. S Connett 1996 First dual protease inhibitor combination shows promise Bioworld Today 7 1 Connett S. First dual protease inhibitor combination shows promise. Bioworld Today 1996 Jul 11; 7: 1 & 3
28. 28. L Prescott 1996 Redefining the approach to treating HIV infection Inpharma 1052 13 4 Prescott L. Redefining the approach to treating HIV infection. Inpharma 1996 Aug 30; 1052: 13–4
29. 29. Henry K, Lamarca A, Myers R, et al. The safety of Viracept™ (nelfinavir mesylate, NFV) in pivotal phase II/III double-blind randomized controlled trials as monotherapy and in combination with either d4T or AZT/3TC [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC
30. 30. SG Deeks M Smith M Holodniy 1997 HIV-1 protease inhibitors: a review for clinicians JAMA 277 2 145 153 8990341 10.1001/jama.1997.03540260059037 1:CAS:528:DyaK2sXnvFaqsw%3D%3D Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277(2): 145–153